Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
read more
Citations
Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC)
AACR 2019 — Congrès de l’association américaine de recherche contre le cancer
Increasing radiosensitivity by the combined inhibition of PARP1 and PI3K in BRCA1-mutated triple negative breast cancer
The Role of the Ste20-like Kinase in Embryonic Development and Neu-induced Mammary Tumorigenesis
Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study
References
Comprehensive molecular portraits of human breast tumours
AKT/PKB signaling: navigating downstream.
The phosphoinositide 3-kinase pathway.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Related Papers (5)
Comprehensive molecular portraits of human breast tumours
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Frequently Asked Questions (7)
Q2. What were the common adverse events in the LOTUS trial?
The most common grade 3 or worse adverse events were diarrhoea (14 [23%] of 61 ipatasertib-treated patients vs none of 62 placebo-treated patients), neutrophil count decreased (five [8%] vs four [6%]), and neutropenia (six [10%] vs one [2%]).
Q3. What was the primary endpoint of the LOTUS trial?
The co-primary endpoints were progression-free survival in the intention-to-treat population and progression-free survival in the PTEN-low (by immunohistochemistry) population.
Q4. What is the main purpose of the study?
The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer.
Q5. How many patients were enrolled in the LOTUS trial?
In this randomised, placebo-controlled, double-blind, phase 2 trial, women aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-negative breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium.
Q6. How many patients were randomly assigned to ipatasertib?
Enrolled patients were randomly assigned (1:1) to receive intravenous paclitaxel 80 mg/m² (days 1, 8, 15) with either ipatasertib 400 mg or placebo once per day (days 1–21) every 28 days until disease progression or unacceptable toxicity.
Q7. How long did the LOTUS trial last?
Median progression-free survival in the intention-to-treat population was 6·2 months (95% CI 3·8–9·0) with ipatasertib versus 4·9 months (3·6–5·4) with placebo (stratified hazard ratio [HR] 0·60, 95% CI 0·37–0·98; p=0·037) and in the 48 patients with PTEN-low tumours, median progression-free survival was 6·2 months (95% CI 3·6–9·1) with ipatasertib versus 3·7 months (1·9–7·3) with placebo (stratified HR 0·59, 95% CI 0·26–1·32, p=0·18).